🔗 Permalink

Assignee profile:

PROTEOSYS AG

City:

Mainz

Country:

Germany

Published Applications:

Last publication date:

2014-10-30

Patent Grants:

Last grant date:

2010-11-02

Top Inventors for applications by PROTEOSYS AG

These are the the leading inventors for applications assigned to PROTEOSYS AG:

André Schrattenholz 18 Mainz, Germany
HELMUT KLOCKER 2 INZING, Austria
Vukic Soskic 2 London, United Kingdom
Wojciech Wozny 1 Nieder-Olm, Germany

Herman Rogatsch 1 Klagenfurt, Austria
Gerhard Schwall 1 Mainz, Germany
Hermann Rogatsch 1 Klagenfurt, Austria
Michael Cahill 1 Loerzweiler, Germany

Michael Cahill 1 D-Loerzweiler, Germany
Slobodan Poznanovic 1 Mainz, Germany
Michael Cahill 1 Lorzweiler, Germany
Hermann Rogatsch 1 Innsbruck, Austria

Michael Cahill 1 New South Wales, Australia
Hans Neuhauer 1 Tuebingen, Germany

Recent patent applications by PROTEOSYS AG

PROTEOSYS AG based in Mainz, DE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2014-10-30

US20140323408A1

Chemistry; metallurgy

METHOD OF INHIBITING DOPAMINERGIC CELL DEATH

#2 | 2014-09-18

US20140271922A1

Chemistry; metallurgy

PIRENZEPINE AS AN AGENT IN CANCER TREATMENT

#3 | 2014-08-28

US20140243270A1

Human necessities

PHARMACEUTICAL COMPOSITION CONTAINING NEUREGULIN ISOFORMS

#4 | 2014-08-28

US20140243269A1

Chemistry; metallurgy

METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS

#5 | 2011-12-01

US20110294791A1

Chemistry; metallurgy

PIRENZEPINE AS AN AGENT IN CANCER TREATMENT

#6 | 2011-10-27

US20110263574A1

Chemistry; metallurgy

PIRENZEPINE AS OTOPROTECTIVE AGENT

#7 | 2011-07-21

US20110177536A1

Chemistry; metallurgy

NOVEL ANTIBODIES RECOGNIZING NATIVE ANNEXIN A3

#8 | 2011-06-16

US20110143366A1

Physics

PROTEIN BIOMARKERS FOR IN VITRO TESTING OF DEVELOPMENTAL TOXICITY AND ENBRYOTOXICITY OF CHEMICAL SUBSTANCES

#9 | 2010-11-02 ✅ Patent 7,824,923 granted on 2010-11-02

US10485870

Neuregulin-β isoforms associated with neuronal processes

#10 | 2010-10-07

US20100256066A1

Human necessities

ACTIVE SOLUBLE POST-TRANSLATIONALLY MODIFIED NEUREGULIN ISOFORMS

#11 | 2010-09-16 ✅ Patent 8,012,697 granted on 2011-09-06

US20100233160A1

Chemistry; metallurgy

Monoclonal anti-annexin A3 antibodies for the detection of prostate carcinoma

#12 | 2010-05-27 ✅ Patent 8,377,648 granted on 2013-02-19

US20100129834A1

Physics

Autoimmune regulation of prostate cancer by annexin A3

#13 | 2009-12-24

US20090318354A1

Human necessities

Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)

#14 | 2009-11-19 ✅ Patent 7,919,582 granted on 2011-04-05

US20090286273A1

Chemistry; metallurgy

Neuregulin-β isoform

#15 | 2009-07-02 ✅ Patent 7,998,970 granted on 2011-08-16

US20090170889A1

Chemistry; metallurgy

Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders

#16 | 2009-05-26 ✅ Patent 7,538,197 granted on 2009-05-26

US10203450

Use of neuregulin-β as an indicator and/or target

#17 | 2007-12-27

US20070298448A1

Chemistry; metallurgy

Enrichment of Enzymatic Cleavage Products

#18 | 2007-11-15 ✅ Patent 8,466,144 granted on 2013-06-18

US20070265251A1

Human necessities

Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents

#19 | 2007-09-06 ✅ Patent 8,039,464 granted on 2011-10-18

US20070207998A1

Human necessities

Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases

#20 | 2007-07-26

US20070172900A1

Chemistry; metallurgy

Diagnostic marker for cancer

#21 | 2005-06-16 ✅ Patent 7,759,068 granted on 2010-07-20

US20050130876A1

Physics

Use of substances for treating tumors

AssigneeID:

76371 ⎘